Underground Biohacking

CJC-1295 + Ipamorelin blend calculator

This vial

5 mg CJC-1295 + 5 mg Ipamorelin (10 mg total)

mL
mcg

1 mg = 1000 mcg.

Your syringe
Draw this much
0.0units

0.060 mL · 2,500 mcg/mL

510152025301020306.0
0 units0.3 mL barrel, U-100 scale30 units
Draw
0.060 mL
Total per draw
300 mcg
Doses per vial
33.3
Reference only · Not medical advice

This draw also delivers 150 mcg Ipamorelin.

CJC-1295 concentration2,500 mcg/mL
Ipamorelin concentration2,500 mcg/mL

Blends come as one vial with a fixed mix, so every draw carries both compounds in this ratio. Running two separate vials? That is a stack: see the CJC-1295 + Ipamorelin stack page.

CJC-1295 draw

Vial5 mg CJC-1295 + 5 mg Ipamorelin (10 mg total)
CJC-1295 in this vial5 mg
Water2 mL
Concentration2,500 mcg/mL
Dose150 mcg
Draw6 units
Syringe0.3 mL, U-100
Also delivers Ipamorelin150 mcg

www.undergroundbiohacking.com · For tracking and calculation purposes only. Not medical advice.

For tracking and calculation purposes only. Not medical advice. Based on a standard U-100 insulin syringe.

How the units are worked out

Your vial holds a fixed amount of peptide. The water you add sets the concentration (how much peptide sits in each millilitre). The concentration then decides how much liquid carries your dose.

Three steps, in order:

  1. Concentration (mcg/mL) = peptide in the vial (mcg) divided by water added (mL).
  2. Volume (mL) = your dose (mcg) divided by the concentration (mcg/mL).
  3. Units to draw = volume (mL) multiplied by 100.

That last step is the syringe, not the peptide. A U-100 insulin syringe is marked so 100 units hold 1 mL, so 0.1 mL reads as 10 units.

A worked example

These are the numbers in the calculator above, worked through: 5 mg CJC-1295 of the 10 mg vial + 2 mL = 2,500 mcg/mL. 150 mcg = 0.06 mL = 6 units on a 0.3 mL syringe, which also delivers 150 mcg Ipamorelin.

Change any number in the tool and this line changes with it. The link in your address bar carries the numbers, so you can save it or send it to yourself.

Water and units at a glance

The vial sizes CJC-1295 + Ipamorelin: The Growth Hormone Stack is sold in, at different water volumes, with CJC-1295 as the amount you name. Every row opens the calculator on that mix.

Vial totalWaterCJC-1295 unitsSame draw delivers
10 mg1 mL3 units150 mcg Ipamorelin
10 mg2 mL6 units150 mcg Ipamorelin
10 mg3 mL9 units150 mcg Ipamorelin
10 mg5 mL15 units150 mcg Ipamorelin

You never choose the Ipamorelin column. The vial is one fixed mix, so it comes out of the same draw.

Composition as sold by vendors in our register; most-used water and draw from WPA dosing data, Aug 2026. Not a recommendation.

Mixing and storage

Run the water down the inside wall of the vial and let the powder dissolve on its own. Never shake it. Label the vial with the compound, the total mass, the water you added, the concentration and the date. A sealed freeze-dried vial keeps 12 to 24 months in the fridge at 2 to 8°C. Once mixed with preserved water, such as bacteriostatic water, that drops to roughly 28 days refrigerated. Keep it at the back of the fridge, away from light and away from the door's temperature swings.

Other compounds

Questions

Can I start with lower doses and titrate up?
Yes. Many users start with 50 mcg CJC-1295 and 50 mcg Ipamorelin three times daily for week 1, then move to full doses. Titration reduces headache risk. Observe your response before jumping to full protocol; if you tolerate it well, move to target doses by week 2.
How long before I see recovery differences in training?
Sleep and joint comfort typically improve by week 2-3. Measurable soft-tissue recovery (faster resolution of minor aches) emerges by week 4-6. If you see no change by week 6, IGF-1 may not be responding; request a midpoint blood test to assess.
What if I feel tingling in my fingers or carpal tunnel pain?
This signals GH is elevated enough to shift fluid and nerve pressure. Reduce Ipamorelin to 75 mcg per dose, increase water intake, and monitor for 3-5 days. If it persists, reduce again or consider a washout. This is not dangerous but is your body's signal to dial back.
Can I stack this with other compounds like BPC-157 or TB-500?
Yes. In fact, many users combine this GH stack with tissue-specific peptides like BPC-157 for accelerated local recovery. Space injections 2-3 hours apart and monitor for additive side effects. Research on combined peptide safety is limited, so go conservative with doses.
What happens if I miss a dose of Ipamorelin?
One missed dose will not derail your cycle. If you miss a full day, resume the next day at the regular schedule. If you miss multiple days, the cumulative GH response dips slightly, but the CJC-1295 will maintain baseline GH elevation. Consistency matters, but one or two lapses are not critical.
Do I need bloodwork during the cycle?
Baseline IGF-1 and fasting glucose pre-cycle are recommended. A midpoint check (week 6) confirms you are responders. Post-cycle (week 14, after washout) allows you to observe IGF-1 recovery. If your baseline IGF-1 is already high-normal, skip the stack or use lower doses.

References

  1. 01Teichman SL, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism. PMID: 16352683. DOI: 10.1210/jc.2005-1536.
  2. 02Ionescu M, Frohman LA (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism. PMID: 17018654. DOI: 10.1210/jc.2006-1702.
  3. 03Jette L, et al. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. PMID: 15817669. DOI: 10.1210/en.2004-1286.
  4. 04Mayfield CK, et al. (2026). Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American journal of sports medicine. PMID: 41476424. DOI: 10.1177/03635465251357593.
  5. 05Dominikowski A, et al. (2026). The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Frontiers in endocrinology. PMID: 42395176. DOI: 10.3389/fendo.2026.1822475.
  6. 06Gajda PM, et al. (2019). Glycine-modified growth hormone secretagogues identified in seized doping material. Drug testing and analysis. PMID: 30136411. DOI: 10.1002/dta.2489.
  7. 07Coutinho LFD, et al. (2026). A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. The Journal of sports medicine and physical fitness. PMID: 41880199. DOI: 10.23736/S0022-4707.26.17773-1.
  8. 08Knoop A, et al. (2016). Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS. Analytical and bioanalytical chemistry. PMID: 26879649. DOI: 10.1007/s00216-016-9377-3.
  9. 09Gobburu JV, et al. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical research. PMID: 10496658. DOI: 10.1023/a:1018955126402.
  10. 10Beck DE, et al. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International journal of colorectal disease. PMID: 25331030. DOI: 10.1007/s00384-014-2030-8.
  11. 11Raun K, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European journal of endocrinology. PMID: 9849822. DOI: 10.1530/eje.0.1390552.
  12. 12Andersen NB, et al. (2001). The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth hormone & IGF research. PMID: 11735244. DOI: 10.1054/ghir.2001.0239.
  13. 13Svensson J, et al. (2000). The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. The Journal of endocrinology. PMID: 10828840. DOI: 10.1677/joe.0.1650569.
  14. 14Greenwood-Van Meerveld B, et al. (2012). Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. Journal of experimental pharmacology. PMID: 27186127. DOI: 10.2147/JEP.S35396.
  15. 15Lall S, et al. (2001). Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochemical and biophysical research communications. PMID: 11162489. DOI: 10.1006/bbrc.2000.4065.
  16. 16Adeghate E, Ponery AS (2004). Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuro endocrinology letters. PMID: 15665799.
Chris Hallewell, founder of Underground Biohacking

By , Founder, Underground Biohacking

Last reviewed

The numbers here describe your own vial. They are not medical advice and not a dose suggestion. Confirm your protocol with a qualified clinician.

The full CJC-1295 + Ipamorelin pageRunning a full cycle?
Worth a look
The book

The Peptide Edge

A clear framework instead of guesswork.

Read more
Sourcing

Recommended Sources

The sources we've assessed against published testing criteria.

View
Coming Soon

The UB App

Run the plan, track it, see what changed.

Join the waitlist